Key Highlights
•
A large real-world study shows that the drug burosumab significantly improves growth in children and adolescents with the rare bone disorder X-linked hypophosphatemia (XLH), with modeling predicting it will lead to greater adult height. This finding provides strong evidence for the long-term benefits of this targeted therapy in a real-world setting, offering hope for better outcomes in this genetic condition.
Source →
•
A network meta-analysis of treatments for sacroiliac joint pain found that radiofrequency-based techniques consistently provided better pain relief and reduced disability compared to steroid injections or conservative care. This analysis helps clarify the most effective interventional options for a common cause of chronic low back pain, though it notes that more high-quality, long-term studies are still needed.
Source →
•
A study in female mice with Alzheimer’s-related pathology found that a drug (MW151) that calms brain inflammation improved sleep and circadian rhythm disruptions without reducing amyloid plaques. This suggests that targeting neuroinflammation could be a rapid way to treat sleep problems in Alzheimer’s, which are often an early and distressing symptom, especially for women.
Source →
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
